DE

512.11

-1.31%↓

FDX

236.01

-1.14%↓

PAYX

143.28

-1.38%↓

CPRT

47.43

-1.21%↓

HEICA

245.63

+1.51%↑

DE

512.11

-1.31%↓

FDX

236.01

-1.14%↓

PAYX

143.28

-1.38%↓

CPRT

47.43

-1.21%↓

HEICA

245.63

+1.51%↑

DE

512.11

-1.31%↓

FDX

236.01

-1.14%↓

PAYX

143.28

-1.38%↓

CPRT

47.43

-1.21%↓

HEICA

245.63

+1.51%↑

DE

512.11

-1.31%↓

FDX

236.01

-1.14%↓

PAYX

143.28

-1.38%↓

CPRT

47.43

-1.21%↓

HEICA

245.63

+1.51%↑

DE

512.11

-1.31%↓

FDX

236.01

-1.14%↓

PAYX

143.28

-1.38%↓

CPRT

47.43

-1.21%↓

HEICA

245.63

+1.51%↑

Search

Ocugen Inc

Fechado

1.14

Visão Geral

Variação de preço das ações

24h

Atual

Mín

1.11

Máximo

1.18

Indicadores-chave

By Trading Economics

Rendimento

-1.5M

-15M

Vendas

717K

1.5M

Margem de lucro

-1,036.462

Funcionários

95

EBITDA

-350K

-14M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+334.78% upside

Dividendos

By Dow Jones

Próximos Ganhos

7 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

79M

283M

Abertura anterior

1.14

Fecho anterior

1.14

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Ocugen Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de jul. de 2025, 22:19 UTC

Aquisições, Fusões, Aquisições de Empresas

FCC Approves U.S. Cellular Sale to T-Mobile

11 de jul. de 2025, 17:28 UTC

Grandes Movimentos do Mercado

SharpLink Gaming Gains on Ethereum Purchase

11 de jul. de 2025, 16:57 UTC

Ganhos

BASF Cuts Outlook on Global Economy Uncertainty

11 de jul. de 2025, 21:45 UTC

Conversa de Mercado

Fitch Affirms Germany's Rating, Sees Deficit, Debt Rising -- Market Talk

11 de jul. de 2025, 19:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Kraft Heinz Might Split Up, Report Says. What Investors Need to Know. -- Barrons.com

11 de jul. de 2025, 19:45 UTC

Conversa de Mercado

Crude Futures Post Back-to-Back Weekly Gains -- Market Talk

11 de jul. de 2025, 19:05 UTC

Conversa de Mercado

U.S. Natural Gas Futures Post Third Straight Weekly Loss -- Market Talk

11 de jul. de 2025, 18:18 UTC

Conversa de Mercado

Canada Officials Tight-Lipped on Next Steps in Trump Trade Talks -- Market Talk

11 de jul. de 2025, 17:35 UTC

Conversa de Mercado

Canada Should Target Lower Sectoral Tariffs, Import Quotas in US Trade Talks -- Market Talk

11 de jul. de 2025, 17:26 UTC

Conversa de Mercado

U.S. Oil Rig Count Down by 1 to 424 -- Market Talk

11 de jul. de 2025, 16:53 UTC

Conversa de Mercado

Crude Futures Add to Early Gains -- Market Talk

11 de jul. de 2025, 16:42 UTC

Ganhos

BASF Cuts Outlook on Global Economic Uncertainty

11 de jul. de 2025, 16:08 UTC

Conversa de Mercado

Rise in Canadian Staycations May Help Explain Labor Market Strength -- Market Talk

11 de jul. de 2025, 16:05 UTC

Ganhos

BASF Will Publish Half-Year Results on July 30

11 de jul. de 2025, 16:04 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

11 de jul. de 2025, 16:04 UTC

Conversa de Mercado

Senior Housing Shortage Gives REITs Pricing Power -- Market Talk

11 de jul. de 2025, 16:03 UTC

Ganhos

BASF: Guidance Cut Is Due to Ongoing Macroeconomic, Geopolitical Uncertainties

11 de jul. de 2025, 16:02 UTC

Ganhos

BASF Continues to Expect Free Cash Flow Between EUR400M and EUR800M in 2025

11 de jul. de 2025, 16:01 UTC

Ganhos

BASF Had Seen Ebitda Before Special Items Between EUR8B and EUR8.4B in 2025

11 de jul. de 2025, 16:00 UTC

Ganhos

BASF Now Sees Ebitda Before Special Items Between EUR7.3B and EUR7.7B in 2025

11 de jul. de 2025, 15:59 UTC

Ganhos

BASF Cuts 2025 Earnings View

11 de jul. de 2025, 15:58 UTC

Ganhos

Nvidia's CEO Has Sold a Million Shares. He Has Millions More to Sell. -- Barrons.com

11 de jul. de 2025, 15:57 UTC

Ganhos

BASF 2Q EBIT Before Special Items EUR810M

11 de jul. de 2025, 15:54 UTC

Ganhos

BASF: Analysts Had Expected 2Q Sales of EUR15.80B

11 de jul. de 2025, 15:54 UTC

Ganhos

BASF 2Q Sales Fell 2.1% on Year

11 de jul. de 2025, 15:53 UTC

Ganhos

BASF 2Q Sales EUR15.77B

11 de jul. de 2025, 15:52 UTC

Ganhos

BASF: This Was in Line With Consensus Estimates

11 de jul. de 2025, 15:52 UTC

Ganhos

BASF 2Q Ebitda Before Special Items EUR1.77B

11 de jul. de 2025, 15:49 UTC

Ganhos

BASF Reports Preliminary 2Q Figures, Adjusts 2025 Outlook

11 de jul. de 2025, 15:41 UTC

Conversa de Mercado

Oil, Gas Prices Not Seen Supporting Drilling Boom -- Market Talk

Comparação entre Pares

Variação de preço

Ocugen Inc Previsão

Preço-alvo

By TipRanks

334.78% parte superior

Previsão para 12 meses

Média 5 USD  334.78%

Máximo 8 USD

Mínimo 1 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Ocugen Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

4 ratings

3

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

0.6818 / 0.74Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

No Evidence

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.